Clinical characteristics of elderly patients with heart failure : what
... tients as well as the effects of contemporary thera‑ pies on the outcomes of these patients. This is be‑ cause most clinical trials on HF excluded this pop‑ ulation, especially persons over 75 years of age.2,3 Except more frequent comorbidities such as hypertension, coronary artery disease [CAD], or ...
... tients as well as the effects of contemporary thera‑ pies on the outcomes of these patients. This is be‑ cause most clinical trials on HF excluded this pop‑ ulation, especially persons over 75 years of age.2,3 Except more frequent comorbidities such as hypertension, coronary artery disease [CAD], or ...
Images and Case Reports in Heart Failure
... he use of left ventricular assist devices (LVADs) in the management of advanced heart failure has grown substantially in recent years, with implantation of these devices increasing 10-fold since the approval of a continuous-flow device for destination therapy in January 2010. With the significant in ...
... he use of left ventricular assist devices (LVADs) in the management of advanced heart failure has grown substantially in recent years, with implantation of these devices increasing 10-fold since the approval of a continuous-flow device for destination therapy in January 2010. With the significant in ...
Cardiac Performance of an Athletic Teleost
... to increases in output pressure. Maximum cardiac output was 76.5 ml.min-l .kg body mass-1, more than 70% higher than maximum cardiac output recorded for hearts of eels and trout. Maximum power output of the heart was 8.7 mW.g ventricle mass-1, the highest power output recorded for any fish heart pre ...
... to increases in output pressure. Maximum cardiac output was 76.5 ml.min-l .kg body mass-1, more than 70% higher than maximum cardiac output recorded for hearts of eels and trout. Maximum power output of the heart was 8.7 mW.g ventricle mass-1, the highest power output recorded for any fish heart pre ...
lec 3 ( heart assessment part 2).
... – Non-specific: enzyme elevated with damage to many body tissues. (i.e. heart, liver, skeletal muscle, brain and RBC’s); Not frequently used today. – Elevates in 1 to 3 days – Peaks in 2 to 5 days ...
... – Non-specific: enzyme elevated with damage to many body tissues. (i.e. heart, liver, skeletal muscle, brain and RBC’s); Not frequently used today. – Elevates in 1 to 3 days – Peaks in 2 to 5 days ...
Canine and Feline Electrocardiography
... – SA node is the primary pacemaker of the heart, but any cells of conduction system can initiate their own impulses under right circumstances – The further down in the conduction system, the slower the rate of automaticity ...
... – SA node is the primary pacemaker of the heart, but any cells of conduction system can initiate their own impulses under right circumstances – The further down in the conduction system, the slower the rate of automaticity ...
American Journal Cardiovascular Drugs 2012
... range of chronic cardiovascular disorders including HF, independent of other risk factors and clinical variables.[7,8] In the placebo arm of the SHIFT study, patients with the highest HR (‡87 beats/min) had more than twice the risk of primary endpoint compared with those with a lower HR (70 to <72 b ...
... range of chronic cardiovascular disorders including HF, independent of other risk factors and clinical variables.[7,8] In the placebo arm of the SHIFT study, patients with the highest HR (‡87 beats/min) had more than twice the risk of primary endpoint compared with those with a lower HR (70 to <72 b ...
Cardiovasular-Heart-2404heart02-22-07
... • Signals ventricles to contract quickly and irregularly ...
... • Signals ventricles to contract quickly and irregularly ...
Left Ventricular Assist Device Reliable assistant for your heart
... Reliable assistant for your heart ...
... Reliable assistant for your heart ...
Understanding Advances in Clinical Electrophysiology: Updates in
... • Patients resuscitated from sudden cardiac arrest or who previously had a lifethreatening ventricular arrhythmia not related to a transient event or correctable cause (secondary prevention). Medical therapy is limited (amiodarone) and has toxicity issues. Implantation of ICDs in this group reduces ...
... • Patients resuscitated from sudden cardiac arrest or who previously had a lifethreatening ventricular arrhythmia not related to a transient event or correctable cause (secondary prevention). Medical therapy is limited (amiodarone) and has toxicity issues. Implantation of ICDs in this group reduces ...
Drugs for Heart Failure
... potential when used regularly- no use in the longterm management of CHF. ...
... potential when used regularly- no use in the longterm management of CHF. ...
Pimobendan in Chronic Right Heart Failure in a Left Ventricular
... furosemide and inotropic therapy (dobutamine). Yet, successful catecholamine weaning was possible not before repeated intravenous levosimendan loading. At that point, all conservative medical heart failure medication including phosphodiesterase inhibitor therapy was exhausted, while levosimendan adm ...
... furosemide and inotropic therapy (dobutamine). Yet, successful catecholamine weaning was possible not before repeated intravenous levosimendan loading. At that point, all conservative medical heart failure medication including phosphodiesterase inhibitor therapy was exhausted, while levosimendan adm ...
left ventricular reverse remodeling with biventricular versus right
... Background: In patients with heart failure (HF), biventricular pacing (BIV) attenuates adverse left ventricular (LV) remodeling in addition to improving survival and relieving symptoms. However, little is known about the effects of BIV pacing in HF patients with atrioventricular (AV) block. Methods: ...
... Background: In patients with heart failure (HF), biventricular pacing (BIV) attenuates adverse left ventricular (LV) remodeling in addition to improving survival and relieving symptoms. However, little is known about the effects of BIV pacing in HF patients with atrioventricular (AV) block. Methods: ...
Inpatient Cardiovascular Medicine. Hospital Medicine: Current Concepts Brochure
... The first book developed specifically for hospitalists managing the growing number of patients with cardiovascular disorders Cardiovascular disease is a major cause of hospitalization and mortality worldwide, and will account for approximately twenty million deaths in 2015. Due to this growing probl ...
... The first book developed specifically for hospitalists managing the growing number of patients with cardiovascular disorders Cardiovascular disease is a major cause of hospitalization and mortality worldwide, and will account for approximately twenty million deaths in 2015. Due to this growing probl ...
contractility
... Also referred to as systolic HF. Randomized clinical trials have mainly enrolled patients with HFrEF and it is only in these patients that efficacious therapies have been demonstrated to date. Also referred to as diastolic HF. Several different criteria have been used to further define HFpEF. The di ...
... Also referred to as systolic HF. Randomized clinical trials have mainly enrolled patients with HFrEF and it is only in these patients that efficacious therapies have been demonstrated to date. Also referred to as diastolic HF. Several different criteria have been used to further define HFpEF. The di ...
BIO 420 Mammalian Physiology Name: Homework #3 Fall 2015 1
... 1. What are the characteristics of cardiac muscle cells which distinguish them from skeletal muscle, and how do these contribute to their ability to perform functions specific to the myocardium? (3 pts) ...
... 1. What are the characteristics of cardiac muscle cells which distinguish them from skeletal muscle, and how do these contribute to their ability to perform functions specific to the myocardium? (3 pts) ...
心力衰竭 - 浙江大学
... Stage A: Patient at high risk for developing HF with no structural disorder of the heart Stage B: Patient with structural disorder without symptoms of HF Stage C: Patient with past or current symptoms of HF associated with underlying structural heart disease Stage D: Patient with end-stage disease w ...
... Stage A: Patient at high risk for developing HF with no structural disorder of the heart Stage B: Patient with structural disorder without symptoms of HF Stage C: Patient with past or current symptoms of HF associated with underlying structural heart disease Stage D: Patient with end-stage disease w ...
Case Study - CONGESTIVE HEART FAILURE, male
... The patient benefitted by L-Carnitine and Lipoic Acid supplementation which could not have been assessed in this patient without SpectraCell’s micronutrient testing. A publication in the American Journal of Cardiology from June 2, 2008 detailed how the addition of Amino Acids including L-Carnitine, ...
... The patient benefitted by L-Carnitine and Lipoic Acid supplementation which could not have been assessed in this patient without SpectraCell’s micronutrient testing. A publication in the American Journal of Cardiology from June 2, 2008 detailed how the addition of Amino Acids including L-Carnitine, ...
SIGN 94: Cardiac arrhythmias in coronary heart disease
... • Implantable Cardioverter Defibrillators in primary & secondary prevention • Antiarrhythmic drug therapy ...
... • Implantable Cardioverter Defibrillators in primary & secondary prevention • Antiarrhythmic drug therapy ...
close
... Prukinje fibers rapidly transmit Impulses up the ventricle All contractile cells at apex Contract simultaneously ...
... Prukinje fibers rapidly transmit Impulses up the ventricle All contractile cells at apex Contract simultaneously ...
Pediatric Dysrhythmias Board Review
... Vital to be aware of arrhythmias that occur in otherwise healthy children Management is individualized Does child have history of heart disease? ...
... Vital to be aware of arrhythmias that occur in otherwise healthy children Management is individualized Does child have history of heart disease? ...
Nervous System Review A. The nervous system can be split into the
... The nervous system can be split into the CNS and the ____________________. The CNS contains the ____________________ and the ____________________. The peripheral nervous system, which contains the peripheral nerves, can be split into two main divisions, ____________________ and ____________________. ...
... The nervous system can be split into the CNS and the ____________________. The CNS contains the ____________________ and the ____________________. The peripheral nervous system, which contains the peripheral nerves, can be split into two main divisions, ____________________ and ____________________. ...
File
... which stands for Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. The VAD used in this study was the HeartMate VE (Long et al., 2005). The REMATCH study was conducted between October 1997 and August 2003. REMATCH showed that the long-term use of this VAD ...
... which stands for Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. The VAD used in this study was the HeartMate VE (Long et al., 2005). The REMATCH study was conducted between October 1997 and August 2003. REMATCH showed that the long-term use of this VAD ...
Clinical Practice Guideline for the Management of Chronic Heart
... Heart failure (HF) is a major and growing public health problem in the United States. Approximately 5 million patients in the country have heart failure and there will be approximately 550,000 new cases of heart failure each year. Heart failure accounts for approximately 12 to 15 million office visi ...
... Heart failure (HF) is a major and growing public health problem in the United States. Approximately 5 million patients in the country have heart failure and there will be approximately 550,000 new cases of heart failure each year. Heart failure accounts for approximately 12 to 15 million office visi ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.